Cooper Companies (COO)
Market Price (7/2/2026): $71.95 | Market Cap: $14.0 BilInvestor Relations Sector: Health Care | Industry: Health Care Supplies
Cooper Companies (COO)
Market Price (7/2/2026): $71.95Market Cap: $14.0 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 23%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% Low stock price volatilityVol 12M is 31% Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Health & Wellness Innovations. Themes include Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -55%, 3Y Excs Rtn is -96% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 28x, P/EPrice/Earnings or Price/(Net Income) is 60x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.6% Key risksCOO key risks include [1] challenges from its extensive international operations, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 23%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Low stock price volatilityVol 12M is 31% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Health & Wellness Innovations. Themes include Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -55%, 3Y Excs Rtn is -96% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 28x, P/EPrice/Earnings or Price/(Net Income) is 60x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -2.6% |
| Key risksCOO key risks include [1] challenges from its extensive international operations, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/1/2026
Cooper Companies (COO) stock has remained largely at the same level since 3/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Earnings Beat Counterbalanced by Cautious Near-Term Outlook.
Cooper Companies reported robust fiscal Q2 2026 results on June 4, 2026, with revenue increasing 8% year-over-year to $1.08 billion, surpassing the $1.05 billion forecast, and non-GAAP earnings per share (EPS) reaching $1.21, exceeding the $1.10 consensus. This performance marked the company's tenth consecutive quarter of beating consensus estimates, leading to an initial stock price increase of 2.78% post-earnings. However, this positive momentum was partially offset by Zacks Research cutting Q3 fiscal 2026 EPS estimates for Cooper Companies to $1.11 from $1.17 on June 24, 2026, reflecting a more cautious near-term outlook for the company.
2. Strategic Progress in CooperSurgical Offset by Regional Weakness and Operational Pressures.
The company announced advancements in its CooperSurgical strategic review, including settlements for substantially all embryo media recall claims and active discussions with multiple interested parties for the business, suggesting potential future value creation. Despite this, the CooperVision segment experienced a 4% revenue decline in the Asia-Pacific region. Additionally, the company continued to face margin pressures from factors such as tariffs, freight costs, and reduced production at CooperVision due to inventory adjustments, leading to a projected Q3 fiscal 2026 gross margin of approximately 66%.
Show more
Cooper Companies (COO) stock has remained largely at the same level since 3/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Earnings Beat Counterbalanced by Cautious Near-Term Outlook.
Cooper Companies reported robust fiscal Q2 2026 results on June 4, 2026, with revenue increasing 8% year-over-year to $1.08 billion, surpassing the $1.05 billion forecast, and non-GAAP earnings per share (EPS) reaching $1.21, exceeding the $1.10 consensus. This performance marked the company's tenth consecutive quarter of beating consensus estimates, leading to an initial stock price increase of 2.78% post-earnings. However, this positive momentum was partially offset by Zacks Research cutting Q3 fiscal 2026 EPS estimates for Cooper Companies to $1.11 from $1.17 on June 24, 2026, reflecting a more cautious near-term outlook for the company.
2. Strategic Progress in CooperSurgical Offset by Regional Weakness and Operational Pressures.
The company announced advancements in its CooperSurgical strategic review, including settlements for substantially all embryo media recall claims and active discussions with multiple interested parties for the business, suggesting potential future value creation. Despite this, the CooperVision segment experienced a 4% revenue decline in the Asia-Pacific region. Additionally, the company continued to face margin pressures from factors such as tariffs, freight costs, and reduced production at CooperVision due to inventory adjustments, leading to a projected Q3 fiscal 2026 gross margin of approximately 66%.
Show more
Updated on 7/1/2026
Cooper Companies (COO) stock has remained largely at the same level since 3/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Earnings Beat Counterbalanced by Cautious Near-Term Outlook.
Cooper Companies reported robust fiscal Q2 2026 results on June 4, 2026, with revenue increasing 8% year-over-year to $1.08 billion, surpassing the $1.05 billion forecast, and non-GAAP earnings per share (EPS) reaching $1.21, exceeding the $1.10 consensus. This performance marked the company's tenth consecutive quarter of beating consensus estimates, leading to an initial stock price increase of 2.78% post-earnings. However, this positive momentum was partially offset by Zacks Research cutting Q3 fiscal 2026 EPS estimates for Cooper Companies to $1.11 from $1.17 on June 24, 2026, reflecting a more cautious near-term outlook for the company.
2. Strategic Progress in CooperSurgical Offset by Regional Weakness and Operational Pressures.
The company announced advancements in its CooperSurgical strategic review, including settlements for substantially all embryo media recall claims and active discussions with multiple interested parties for the business, suggesting potential future value creation. Despite this, the CooperVision segment experienced a 4% revenue decline in the Asia-Pacific region. Additionally, the company continued to face margin pressures from factors such as tariffs, freight costs, and reduced production at CooperVision due to inventory adjustments, leading to a projected Q3 fiscal 2026 gross margin of approximately 66%.
3. Mixed Analyst Sentiment and Broader Healthcare Sector Headwinds.
Analyst ratings for Cooper Companies were mixed, with a consensus ranging from "Buy" to "Hold" and average price targets between $81.31 and $85.00, implying a potential upside of 13% to 18.5% from current trading levels. However, some analysts reduced their price objectives following the Q2 earnings report. This divergent analyst outlook occurred within a challenging macroeconomic environment for the broader healthcare sector, which continued to grapple with significant financial strain due to escalating labor and drug costs, government underpayment, and Medicare Advantage friction, impacting the overall sentiment for medical device companies.
4. Macroeconomic Uncertainty Surrounding Interest Rates.
The overall market was influenced by ongoing macroeconomic uncertainty, particularly regarding interest rates. As of March 31, 2026, the market had largely priced out any Federal Reserve rate cuts for the remainder of fiscal year 2026. Further strong labor market data cooled expectations for near-term rate cuts in late June and early July, contributing to a dip in the S&P 500 on July 1, 2026, as investors focused on economic data and upcoming Federal Reserve comments. This broader market cautiousness likely prevented a sustained upward movement for Cooper Companies' stock.
Show less
Cooper Companies (COO) stock has remained largely at the same level since 3/31/2026 because of the following key factors:
1. Strong Fiscal Q2 2026 Earnings Beat Counterbalanced by Cautious Near-Term Outlook.
Cooper Companies reported robust fiscal Q2 2026 results on June 4, 2026, with revenue increasing 8% year-over-year to $1.08 billion, surpassing the $1.05 billion forecast, and non-GAAP earnings per share (EPS) reaching $1.21, exceeding the $1.10 consensus. This performance marked the company's tenth consecutive quarter of beating consensus estimates, leading to an initial stock price increase of 2.78% post-earnings. However, this positive momentum was partially offset by Zacks Research cutting Q3 fiscal 2026 EPS estimates for Cooper Companies to $1.11 from $1.17 on June 24, 2026, reflecting a more cautious near-term outlook for the company.
2. Strategic Progress in CooperSurgical Offset by Regional Weakness and Operational Pressures.
The company announced advancements in its CooperSurgical strategic review, including settlements for substantially all embryo media recall claims and active discussions with multiple interested parties for the business, suggesting potential future value creation. Despite this, the CooperVision segment experienced a 4% revenue decline in the Asia-Pacific region. Additionally, the company continued to face margin pressures from factors such as tariffs, freight costs, and reduced production at CooperVision due to inventory adjustments, leading to a projected Q3 fiscal 2026 gross margin of approximately 66%.
3. Mixed Analyst Sentiment and Broader Healthcare Sector Headwinds.
Analyst ratings for Cooper Companies were mixed, with a consensus ranging from "Buy" to "Hold" and average price targets between $81.31 and $85.00, implying a potential upside of 13% to 18.5% from current trading levels. However, some analysts reduced their price objectives following the Q2 earnings report. This divergent analyst outlook occurred within a challenging macroeconomic environment for the broader healthcare sector, which continued to grapple with significant financial strain due to escalating labor and drug costs, government underpayment, and Medicare Advantage friction, impacting the overall sentiment for medical device companies.
4. Macroeconomic Uncertainty Surrounding Interest Rates.
The overall market was influenced by ongoing macroeconomic uncertainty, particularly regarding interest rates. As of March 31, 2026, the market had largely priced out any Federal Reserve rate cuts for the remainder of fiscal year 2026. Further strong labor market data cooled expectations for near-term rate cuts in late June and early July, contributing to a dip in the S&P 500 on July 1, 2026, as investors focused on economic data and upcoming Federal Reserve comments. This broader market cautiousness likely prevented a sustained upward movement for Cooper Companies' stock.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 0.6% change in COO stock from 3/31/2026 to 7/1/2026 was primarily driven by a 70.6% change in the company's P/E Multiple.| (LTM values as of) | 3312026 | 7012026 | Change |
|---|---|---|---|
| Stock Price ($) | 71.50 | 71.95 | 0.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,152 | 4,231 | 1.9% |
| Net Income Margin (%) | 9.7% | 5.6% | -42.4% |
| P/E Multiple | 34.9 | 59.5 | 70.6% |
| Shares Outstanding (Mil) | 196 | 195 | 0.4% |
| Cumulative Contribution | 0.6% |
Market Drivers
3/31/2026 to 7/1/2026| Return | Correlation | |
|---|---|---|
| COO | 0.6% | |
| Market (SPY) | 14.7% | -4.8% |
| Sector (XLV) | 8.8% | 55.9% |
Fundamental Drivers
The -12.2% change in COO stock from 12/31/2025 to 7/1/2026 was primarily driven by a -39.2% change in the company's Net Income Margin (%).| (LTM values as of) | 12312025 | 7012026 | Change |
|---|---|---|---|
| Stock Price ($) | 81.96 | 71.95 | -12.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4,092 | 4,231 | 3.4% |
| Net Income Margin (%) | 9.2% | 5.6% | -39.2% |
| P/E Multiple | 43.2 | 59.5 | 37.7% |
| Shares Outstanding (Mil) | 198 | 195 | 1.3% |
| Cumulative Contribution | -12.2% |
Market Drivers
12/31/2025 to 7/1/2026| Return | Correlation | |
|---|---|---|
| COO | -12.2% | |
| Market (SPY) | 9.7% | 26.0% |
| Sector (XLV) | 3.5% | 56.5% |
Fundamental Drivers
The 1.1% change in COO stock from 6/30/2025 to 7/1/2026 was primarily driven by a 73.3% change in the company's P/E Multiple.| (LTM values as of) | 6302025 | 7012026 | Change |
|---|---|---|---|
| Stock Price ($) | 71.16 | 71.95 | 1.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,988 | 4,231 | 6.1% |
| Net Income Margin (%) | 10.4% | 5.6% | -46.3% |
| P/E Multiple | 34.3 | 59.5 | 73.3% |
| Shares Outstanding (Mil) | 200 | 195 | 2.5% |
| Cumulative Contribution | 1.1% |
Market Drivers
6/30/2025 to 7/1/2026| Return | Correlation | |
|---|---|---|
| COO | 1.1% | |
| Market (SPY) | 21.7% | 24.1% |
| Sector (XLV) | 19.9% | 48.7% |
Fundamental Drivers
The -24.9% change in COO stock from 6/30/2023 to 7/1/2026 was primarily driven by a -33.8% change in the company's Net Income Margin (%).| (LTM values as of) | 6302023 | 7012026 | Change |
|---|---|---|---|
| Stock Price ($) | 95.85 | 71.95 | -24.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,427 | 4,231 | 23.4% |
| Net Income Margin (%) | 8.4% | 5.6% | -33.8% |
| P/E Multiple | 65.8 | 59.5 | -9.5% |
| Shares Outstanding (Mil) | 198 | 195 | 1.5% |
| Cumulative Contribution | -24.9% |
Market Drivers
6/30/2023 to 7/1/2026| Return | Correlation | |
|---|---|---|
| COO | -24.9% | |
| Market (SPY) | 74.2% | 37.7% |
| Sector (XLV) | 25.8% | 49.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| COO Return | 15% | -21% | 14% | -3% | -11% | -13% | -21% |
| Peers Return | 7% | -8% | 9% | 14% | 18% | -13% | 26% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| COO Win Rate | 67% | 50% | 58% | 50% | 50% | 33% | |
| Peers Win Rate | 47% | 52% | 50% | 56% | 65% | 29% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| COO Max Drawdown | -18% | -42% | -23% | -18% | -35% | -30% | |
| Peers Max Drawdown | -18% | -23% | -20% | -14% | -20% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, BSX, BLCO, MDT. See COO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/1/2026 (YTD)
How Low Can It Go
| Event | COO | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -20.6% | -9.5% |
| % Gain to Breakeven | 25.9% | 10.5% |
| Time to Breakeven | 84 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -41.0% | -24.5% |
| % Gain to Breakeven | 69.5% | 32.4% |
| Time to Breakeven | 685 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -31.7% | -33.7% |
| % Gain to Breakeven | 46.5% | 50.9% |
| Time to Breakeven | 200 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.7% | -19.2% |
| % Gain to Breakeven | 18.6% | 23.8% |
| Time to Breakeven | 37 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -10.8% | -3.7% |
| % Gain to Breakeven | 12.2% | 3.9% |
| Time to Breakeven | 40 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -30.5% | -12.2% |
| % Gain to Breakeven | 43.8% | 13.9% |
| Time to Breakeven | 164 days | 62 days |
In The Past
Cooper Companies's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | COO | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -20.6% | -9.5% |
| % Gain to Breakeven | 25.9% | 10.5% |
| Time to Breakeven | 84 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -41.0% | -24.5% |
| % Gain to Breakeven | 69.5% | 32.4% |
| Time to Breakeven | 685 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -31.7% | -33.7% |
| % Gain to Breakeven | 46.5% | 50.9% |
| Time to Breakeven | 200 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -30.5% | -12.2% |
| % Gain to Breakeven | 43.8% | 13.9% |
| Time to Breakeven | 164 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -25.7% | -6.8% |
| % Gain to Breakeven | 34.7% | 7.3% |
| Time to Breakeven | 126 days | 15 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -20.7% | -17.9% |
| % Gain to Breakeven | 26.1% | 21.8% |
| Time to Breakeven | 43 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -70.8% | -53.4% |
| % Gain to Breakeven | 242.1% | 114.4% |
| Time to Breakeven | 389 days | 1085 days |
In The Past
Cooper Companies's stock fell 0.0% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Cooper Companies (COO)
```html
The Cooper Companies (COO) is a global medical device company primarily operating in two distinct segments: vision care and women's healthcare. Founded in 1958, the company manufactures and markets a wide range of products designed to improve health and quality of life for its diverse customer base worldwide.
Its CooperVision segment is a leading provider of contact lenses. This division offers an extensive portfolio of lenses, including standard spherical lenses for correcting common near and farsightedness, as well as specialized toric lenses for astigmatism and multifocal lenses addressing presbyopia, myopia, ocular dryness, and eye fatigue. These vision correction solutions serve contact lens wearers across the Americas, Europe, Middle East, Africa, and Asia Pacific regions.
The second key segment, CooperSurgical, focuses on family and women's health. This segment supplies healthcare professionals and patients globally with a broad array of medical devices, fertility solutions, and diagnostic products. Its offerings include surgical and office products like uterine manipulators and the PARAGARD IUD, alongside comprehensive fertility products and services such as consumables, equipment, embryo options, and preimplantation genetic testing.
```AI Analysis | Feedback
Imagine a company that's essentially the contact lens business of an Alcon or the vision care division of Johnson & Johnson, combined with a women's health medical device and fertility company like Hologic.
AI Analysis | Feedback
- Spherical Lenses: Contact lenses that correct common vision impairments such as near and farsightedness.
- Toric and Multifocal Lenses: Specialized contact lenses designed to correct vision challenges including astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues.
- Surgical and Office Medical Devices: A range of products for women's healthcare, including uterine manipulators, retractors, closure products, LEEP products, endosee, illuminate, and fetal pillows.
- PARAGARD: A specific product provided for contraception.
- Fertility Products and Services: Offerings include fertility consumables, equipment, embryo options, and preimplantation genetic testing for reproductive health.
- Genomics and Diagnostics Services: Provide advanced testing and diagnostic solutions for family and women's health.
AI Analysis | Feedback
The Cooper Companies (symbol: COO) primarily sells its products to other companies and healthcare organizations rather than directly to individual consumers in large volumes. Due to the diversified nature of its customer base across its CooperVision and CooperSurgical segments, The Cooper Companies does not publicly disclose the names of its specific major customers.
However, based on its product offerings, its major customer categories include:
* Optical Retailers and Distributors: For its CooperVision segment, which manufactures contact lenses, customers include large optical retail chains, independent optometrists and ophthalmologists, and wholesale distributors who then supply these professionals and retailers.
* Hospitals, Clinics, and Healthcare Systems: For its CooperSurgical segment, which provides medical devices, diagnostics, and surgical products for women's health, customers include general hospitals, specialized clinics (e.g., gynecological clinics), and integrated healthcare systems worldwide.
* Fertility Centers and Clinics: Also within its CooperSurgical segment, customers for fertility products and services (such as fertility consumables, equipment, and genetic testing) are specialized fertility clinics and centers globally.
AI Analysis | Feedback
null
AI Analysis | Feedback
Albert G. White III, President & Chief Executive Officer
Albert G. White III has served as President & Chief Executive Officer of The Cooper Companies since May 2018. Prior to this role, he was Chief Financial Officer from November 2016. He also held positions as Executive Vice President and Chief Strategy Officer. From August 2015 to May 2018, Mr. White directed Cooper's women's healthcare business and served as Chief Executive Officer of Cooper Medical Inc., which is the parent company to CooperSurgical. Before joining Cooper in 2006, he was a Director with KeyBanc Capital Markets for three years and held various leadership roles within KeyBank National Association for eight years. Mr. White currently serves as a board member of Evolvus Inc.
Brian Andrews, Executive Vice President, Chief Financial Officer & Treasurer
Brian Andrews was promoted to Senior Vice President, Chief Financial Officer and Treasurer of The Cooper Companies in May 2018. He assumed the additional role of principal accounting officer in December 2025. Mr. Andrews began his career at Cooper in 2006 as Assistant Treasurer, later serving as Treasurer and Vice President. In 2017, he added the role of Vice President, Global Logistics and Service for CooperSurgical. Before joining Cooper, he held various corporate and investment banking positions at KeyBanc Capital Markets and ING Barings.
Daniel G. McBride, Executive Vice President & Chief Operating Officer
Daniel G. McBride has served as Executive Vice President and Chief Operating Officer of The Cooper Companies since November 2013. His previous roles at Cooper include President of CooperVision from 2014 to 2022, Chief Risk Officer, General Counsel, and Senior Counsel. Before joining Cooper in February 2005, Mr. McBride was an attorney with Latham & Watkins LLP, where he focused on mergers and acquisitions and corporate finance matters.
Jerry Warner, President of CooperVision
Jerry Warner is the President of CooperVision. He is also listed as an insider who has purchased shares of Cooper Companies stock.
Holly Sheffield, President of CooperSurgical
Holly Sheffield serves as the President of CooperSurgical. Insider trading records indicate she has purchased shares of Cooper Companies stock.
AI Analysis | Feedback
The Cooper Companies (COO) faces several key risks to its business, primarily stemming from its operations in contact lenses (CooperVision) and women's healthcare, including fertility products (CooperSurgical).
The most significant key risks include:
* Litigation and Product Recall in CooperSurgical Segment: CooperSurgical, a segment of Cooper Companies focusing on women's healthcare, is currently facing multiple lawsuits and has initiated recalls related to its in-vitro fertilization (IVF) culturing media. This product was found to be defective, leading to "impaired embryo development" and the destruction of embryos, resulting in substantial financial and reputational damage. Law firms are actively pursuing cases against the company, with the parent company, Cooper Companies Inc., also being named in some lawsuits, although it has moved to dismiss some claims asserting it's not involved in the product's marketing or distribution. This ongoing litigation and product recall pose a significant threat due to potential financial penalties and lasting reputational harm in a sensitive market.
* Intense Competitive Pressures: Both the CooperVision and CooperSurgical segments operate in highly competitive industries. The eyecare market, in particular, sees aggressive product launches and marketing strategies from established competitors such as Alcon, Johnson & Johnson, and Bausch + Lomb in daily silicone hydrogel lens segments. Additionally, the rise of private-label and retailer-owned lens ranges is compressing commoditized segments. These competitive dynamics can lead to pricing pressures, market share erosion, and ultimately impact Cooper Companies' revenue and profitability.
* Regulatory Changes and Economic/Political Environment: As a global medical device company, Cooper Companies is exposed to stringent and often unpredictable healthcare regulations worldwide. Economic and trade sanctions, for example, pose a significant risk, potentially complicating operations and increasing costs, especially concerning adherence to regulations from bodies like the U.S. Department of Treasury's Office of Foreign Assets Control and the United Nations Security Council. Furthermore, general economic volatility, inflationary pressures, and geopolitical tensions in various international markets where Cooper Companies operates can adversely affect its business, liquidity, and financial condition.
AI Analysis | Feedback
null
AI Analysis | Feedback
The Cooper Companies, Inc. (symbol: COO) operates in two main segments: CooperVision, focusing on contact lenses, and CooperSurgical, dedicated to family and women's healthcare. The addressable markets for their main products and services are as follows:
CooperVision Segment
- Contact Lenses (overall market including spherical, toric, and multifocal lenses): The global contact lenses market was estimated at approximately $20.24 billion USD in 2024 and is projected to reach about $33.80 billion USD by 2030.
- Toric Lenses (for astigmatism correction): The global astigmatism contact lens market is projected to reach $8.733 billion USD in 2025 and is expected to grow to over $16 billion USD by 2033.
- Multifocal Lenses (for presbyopia correction): The global multifocal contact lenses market size was valued at $3.45 billion USD in 2025 and is projected to grow to $5.89 billion USD by 2034.
- Myopia Treatment (including lenses for myopia control): The global myopia treatment market was valued at approximately $18 billion USD in 2023 and is expected to reach $41 billion USD by the end of 2032.
- Dry Eye Disease (treatment, including related contact lenses for ocular dryness and eye fatigues): The global dry eye disease market size was valued at $6.43 billion USD in 2024 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 4.04% from 2025 to 2034.
CooperSurgical Segment
- Gynecology Surgical Instruments (a proxy for women's health medical devices): The global gynecology surgical instruments market accrued earnings of approximately $9.95 billion USD in 2023 and is predicted to reach about $20.11 billion USD by 2032.
- Fertility Products and Services: The global fertility services market was valued at $51.9 billion USD in 2025 and is estimated to reach $150.2 billion USD by 2034.
- Preimplantation Genetic Testing (PGT, part of genomics/diagnostics): The global preimplantation genetic testing market size was valued at $928.78 billion USD in 2025 and is projected to grow to $1736.79 billion USD by 2034.
- Intrauterine Devices (IUDs, for contraception, e.g., PARAGARD): The global intrauterine devices market was valued at $4 billion USD in 2024 and is expected to grow to $11 billion USD by 2034.
- Uterine Manipulators (surgical and office products): The global uterine manipulation devices market was valued at $367 million USD in 2024 and is expected to grow to $610.7 million USD by 2034.
AI Analysis | Feedback
The Cooper Companies (COO) is anticipated to drive future revenue growth over the next 2-3 years through several key strategies across its CooperVision and CooperSurgical segments.
Here are 4 expected drivers of future revenue growth:
* **Expansion of Premium Daily Disposable Contact Lenses:** CooperVision expects continued robust growth from its premium daily silicone hydrogel lenses, such as MyDay and clariti 1 day, with new product introductions like MyDay Energys further enhancing its portfolio. The MyDay portfolio, in particular, has demonstrated strong momentum and is a significant contributor to sales.
* **Global Scaling of Myopia Management Solutions:** The company is strategically focused on scaling its MiSight 1 day contact lens for myopia management globally. Significant growth has been reported for MiSight, and regulatory approvals and commercialization plans in new markets, including Japan, are expected to capture a share of the projected multi-billion dollar myopia management market.
* **Recovery and Growth within the CooperSurgical Fertility Business:** CooperSurgical anticipates a rebound and sustained growth in its fertility offerings. This includes increased sales of fertility consumables, equipment, and preimplantation genetic testing services, with strategic market entries and approvals planned for regions like Latin America, the Middle East, and India to capitalize on the double-digit growth in IVF cycles.
* **Strategic Geographic Expansion and Market Share Gains:** The Cooper Companies aims to deepen its market penetration and increase sales in key international regions, particularly in the EMEA (Europe, Middle East, Africa) and Asia Pacific markets. This involves localized strategies, optometrist training, and strengthening branded sales, especially among independent practitioners, across both its vision and surgical segments.
AI Analysis | Feedback
Share Repurchases
- In September 2025, CooperCompanies increased its share repurchase program by $1 billion, bringing the total authorization to $2 billion. This program has no specified termination date and can be adjusted or discontinued at any time.
- The company reported $92.5 million in share repurchases during its first quarter of fiscal year 2026, which ended January 31, 2026.
- The expanded repurchase program is part of CooperCompanies' disciplined capital allocation strategy, which balances investments and debt reduction with returning capital to shareholders.
Share Issuance
- On February 20, 2024, Cooper Companies underwent a 4:1 forward stock split.
Outbound Investments
- Cooper Companies made 4 acquisitions in 2021.
- The most significant recent acquisition was Generate, a provider of stem cell storage services, acquired in November 2021 for $1.6 billion.
- Other acquisitions in 2021 included OBP Medical, Safe Obstetric Systems, and SightGlass Vision, though their specific financial details were not disclosed.
Capital Expenditures
- Capital expenditures for the last twelve months (LTM) as of October 28, 2025, amounted to $83 million.
- In the first quarter of fiscal year 2026, capital spending was $102.2 million.
- Projected capital expenditures for fiscal year 2026 are estimated to be $388 million, primarily focused on maintaining existing assets and expanding property, plant, and equipment.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 71.95 |
| Mkt Cap | 63.9 |
| Rev LTM | 20,615 |
| Op Inc LTM | 4,106 |
| FCF LTM | 3,298 |
| FCF 3Y Avg | 2,525 |
| CFO LTM | 4,341 |
| CFO 3Y Avg | 3,543 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.9% |
| Rev Chg 3Y Avg | 7.3% |
| Rev Chg Q | 9.9% |
| QoQ Delta Rev Chg LTM | 2.3% |
| Op Inc Chg LTM | 20.7% |
| Op Inc Chg 3Y Avg | 5.8% |
| Op Mgn LTM | 18.8% |
| Op Mgn 3Y Avg | 18.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 21.1% |
| CFO/Rev 3Y Avg | 19.9% |
| FCF/Rev LTM | 14.9% |
| FCF/Rev 3Y Avg | 14.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 63.9 |
| P/S | 3.1 |
| P/Op Inc | 19.1 |
| P/EBIT | 23.5 |
| P/E | 21.1 |
| P/CFO | 14.7 |
| Total Yield | 5.5% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 2.3% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 8.0% |
| 3M Rtn | -0.8% |
| 6M Rtn | -12.2% |
| 12M Rtn | -1.2% |
| 3Y Rtn | -17.5% |
| 1M Excs Rtn | 9.6% |
| 3M Excs Rtn | -14.0% |
| 6M Excs Rtn | -20.8% |
| 12M Excs Rtn | -19.5% |
| 3Y Excs Rtn | -88.3% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| CooperVision | 2,744 | 2,609 | 2,424 | 2,243 | 2,152 |
| CooperSurgical | 1,349 | 1,286 | 1,170 | 1,065 | 770 |
| Corporate | 0 | 0 | 0 | 0 | 0 |
| Total | 4,092 | 3,895 | 3,593 | 3,308 | 2,922 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| CooperVision | 730 | 676 | 588 | 494 | 481 |
| CooperSurgical | 43 | 118 | 16 | 67 | 72 |
| Corporate | -90 | -89 | -71 | -54 | -47 |
| Total | 683 | 706 | 533 | 508 | 506 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| CooperVision | 7,604 | 7,285 | 7,044 | 6,779 | 6,966 |
| CooperSurgical | 4,619 | 4,832 | 4,352 | 4,408 | 2,396 |
| Corporate | 171 | 198 | 263 | 306 | 245 |
| Total | 12,395 | 12,315 | 11,659 | 11,492 | 9,606 |
Price Behavior
Price Behavior
| Market Price | $71.95 | |
| Market Cap ($ Bil) | 14.0 | |
| First Trading Date | 12/30/1983 | |
| Distance from 52W High | -14.7% | |
| 50 Days | 200 Days | |
| DMA Price | $64.13 | $72.73 |
| DMA Trend | indeterminate | down |
| Distance from DMA | 12.2% | -1.1% |
| 3M | 1YR | |
| Volatility | 30.5% | 30.7% |
| Downside Capture | 0.06 | 73.14 |
| Upside Capture | 2.68 | 54.46 |
| Correlation (SPY) | -4.6% | 24.0% |
COO Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.64 | -0.56 | 0.07 | 0.50 | 0.59 | 0.72 |
| Up Beta | -0.18 | -0.04 | 0.95 | 0.96 | 0.99 | 0.97 |
| Down Beta | -1.40 | -1.19 | -1.54 | 0.04 | 0.16 | 0.47 |
| Up Capture | 48% | 8% | 11% | 25% | 43% | 24% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 12 | 20 | 26 | 52 | 121 | 355 |
| Down Capture | -136% | -107% | 3% | 76% | 75% | 94% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 9 | 21 | 37 | 73 | 130 | 392 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COO | |
|---|---|---|---|---|
| COO | 0.7% | 30.8% | 0.04 | - |
| Sector ETF (XLV) | 20.0% | 15.5% | 0.98 | 48.9% |
| Equity (SPY) | 21.8% | 12.5% | 1.30 | 24.2% |
| Gold (GLD) | 21.7% | 27.7% | 0.69 | 8.0% |
| Commodities (DBC) | 21.4% | 18.6% | 0.90 | -20.0% |
| Real Estate (VNQ) | 13.0% | 13.7% | 0.65 | 41.0% |
| Bitcoin (BTCUSD) | -45.0% | 42.6% | -1.28 | 7.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COO | |
|---|---|---|---|---|
| COO | -5.9% | 29.2% | -0.18 | - |
| Sector ETF (XLV) | 6.7% | 14.8% | 0.27 | 56.3% |
| Equity (SPY) | 13.5% | 17.1% | 0.61 | 51.4% |
| Gold (GLD) | 17.4% | 18.3% | 0.77 | 14.3% |
| Commodities (DBC) | 6.8% | 19.5% | 0.25 | 5.9% |
| Real Estate (VNQ) | 2.8% | 18.8% | 0.05 | 53.2% |
| Bitcoin (BTCUSD) | 11.9% | 53.7% | 0.41 | 21.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COO | |
|---|---|---|---|---|
| COO | 5.7% | 27.9% | 0.24 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.51 | 59.8% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 56.6% |
| Gold (GLD) | 11.9% | 16.1% | 0.60 | 10.1% |
| Commodities (DBC) | 5.6% | 18.0% | 0.24 | 13.2% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.22 | 51.6% |
| Bitcoin (BTCUSD) | 56.6% | 66.3% | 0.97 | 16.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/15/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 6/4/2026 | 8.6% | 8.9% | |
| 3/5/2026 | -4.6% | -10.8% | -12.4% |
| 12/4/2025 | 5.7% | 6.6% | 8.9% |
| 8/27/2025 | -12.9% | -8.2% | -8.8% |
| 5/29/2025 | -14.6% | -11.0% | -11.0% |
| 3/6/2025 | -6.6% | -14.6% | -18.9% |
| 12/5/2024 | -4.4% | -6.3% | -10.2% |
| 8/28/2024 | 11.8% | 12.7% | 16.1% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 14 | 13 |
| # Negative | 11 | 11 | 11 |
| Median Positive | 4.5% | 6.5% | 7.6% |
| Median Negative | -4.4% | -7.6% | -10.2% |
| Max Positive | 11.8% | 12.7% | 16.1% |
| Max Negative | -14.6% | -14.6% | -18.9% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 6/4/2026 | 8.6% | 8.9% | |
| 3/5/2026 | -4.6% | -10.8% | -12.4% |
| 12/4/2025 | 5.7% | 6.6% | 8.9% |
| 8/27/2025 | -12.9% | -8.2% | -8.8% |
| 5/29/2025 | -14.6% | -11.0% | -11.0% |
| 3/6/2025 | -6.6% | -14.6% | -18.9% |
| 12/5/2024 | -4.4% | -6.3% | -10.2% |
| 8/28/2024 | 11.8% | 12.7% | 16.1% |
| 5/30/2024 | 4.5% | 5.6% | -4.3% |
| 2/29/2024 | 9.2% | 9.1% | 6.0% |
| 12/7/2023 | -2.9% | 6.5% | 7.6% |
| 8/30/2023 | -2.9% | -7.1% | -16.5% |
| 6/1/2023 | -4.7% | -6.5% | 0.9% |
| 3/2/2023 | 7.3% | 2.1% | 13.9% |
| 12/8/2022 | -3.1% | 1.5% | 7.6% |
| 8/31/2022 | 4.4% | 7.1% | -8.2% |
| 6/2/2022 | -3.0% | -4.5% | -10.5% |
| 3/3/2022 | 1.8% | -7.6% | 2.7% |
| 12/2/2021 | 3.6% | 8.1% | 11.5% |
| 9/2/2021 | 1.2% | 0.2% | -9.3% |
| 6/3/2021 | -0.6% | -2.6% | 6.2% |
| 3/4/2021 | 4.5% | 2.2% | 4.4% |
| 12/3/2020 | 2.3% | 2.9% | 7.0% |
| 9/3/2020 | 5.4% | 6.5% | 11.7% |
| 6/4/2020 | 1.5% | -11.3% | -9.1% |
| SUMMARY STATS | |||
| # Positive | 14 | 14 | 13 |
| # Negative | 11 | 11 | 11 |
| Median Positive | 4.5% | 6.5% | 7.6% |
| Median Negative | -4.4% | -7.6% | -10.2% |
| Max Positive | 11.8% | 12.7% | 16.1% |
| Max Negative | -14.6% | -14.6% | -18.9% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 04/30/2026 | 06/05/2026 | 10-Q |
| 01/31/2026 | 03/06/2026 | 10-Q |
| 10/31/2025 | 12/05/2025 | 10-K |
| 07/31/2025 | 08/28/2025 | 10-Q |
| 04/30/2025 | 05/30/2025 | 10-Q |
| 01/31/2025 | 03/07/2025 | 10-Q |
| 10/31/2024 | 12/06/2024 | 10-K |
| 07/31/2024 | 08/29/2024 | 10-Q |
| 04/30/2024 | 05/31/2024 | 10-Q |
| 01/31/2024 | 03/01/2024 | 10-Q |
| 10/31/2023 | 12/08/2023 | 10-K |
| 07/31/2023 | 08/31/2023 | 10-Q |
| 04/30/2023 | 06/02/2023 | 10-Q |
| 01/31/2023 | 03/03/2023 | 10-Q |
| 10/31/2022 | 12/09/2022 | 10-K |
| 07/31/2022 | 09/01/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 04/30/2026 | 06/05/2026 | 10-Q |
| 01/31/2026 | 03/06/2026 | 10-Q |
| 10/31/2025 | 12/05/2025 | 10-K |
| 07/31/2025 | 08/28/2025 | 10-Q |
| 04/30/2025 | 05/30/2025 | 10-Q |
| 01/31/2025 | 03/07/2025 | 10-Q |
| 10/31/2024 | 12/06/2024 | 10-K |
| 07/31/2024 | 08/29/2024 | 10-Q |
| 04/30/2024 | 05/31/2024 | 10-Q |
| 01/31/2024 | 03/01/2024 | 10-Q |
| 10/31/2023 | 12/08/2023 | 10-K |
| 07/31/2023 | 08/31/2023 | 10-Q |
| 04/30/2023 | 06/02/2023 | 10-Q |
| 01/31/2023 | 03/03/2023 | 10-Q |
| 10/31/2022 | 12/09/2022 | 10-K |
| 07/31/2022 | 09/01/2022 | 10-Q |
| 04/30/2022 | 06/03/2022 | 10-Q |
| 01/31/2022 | 03/04/2022 | 10-Q |
| 10/31/2021 | 12/10/2021 | 10-K |
| 07/31/2021 | 09/03/2021 | 10-Q |
| 04/30/2021 | 06/04/2021 | 10-Q |
| 01/31/2021 | 03/05/2021 | 10-Q |
| 10/31/2020 | 12/11/2020 | 10-K |
| 07/31/2020 | 09/04/2020 | 10-Q |
| 04/30/2020 | 06/05/2020 | 10-Q |
| 01/31/2020 | 03/06/2020 | 10-Q |
| 10/31/2019 | 12/20/2019 | 10-K |
| 07/31/2019 | 08/30/2019 | 10-Q |
Recent Forward Guidance
Updated 6/5/2026Latest: Q2 2026 Earnings Reported 6/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | 4.29 Bil | 4.30 Bil | 4.32 Bil | -0.5% | Lowered | Guidance: 4.33 Bil for 2026 | |
| 2026 CVI Revenue | 2.88 Bil | 2.90 Bil | 2.91 Bil | -0.8% | Lowered | Guidance: 2.92 Bil for 2026 | |
| 2026 CSI Revenue | 1.40 Bil | 1.41 Bil | 1.41 Bil | 0.1% | Raised | Guidance: 1.41 Bil for 2026 | |
| 2026 Non-GAAP Diluted EPS | 4.58 | 4.62 | 4.66 | 0 | Affirmed | Guidance: 4.62 for 2026 | |
| 2026 Free Cash Flow | 2.20 Bil | 259.2% | Raised | Guidance: 612.50 Mil for 2026 | |||
| 2026 Total Revenue Organic Growth | 3.5% | 4.0% | 4.5% | ||||
| 2026 CVI Revenue Organic Growth | 3.5% | 4.0% | 4.5% | ||||
| 2026 CSI Revenue Organic Growth | 4.0% | 4.5% | 5.0% | ||||
Prior: Q1 2026 Earnings Reported 3/5/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Total Revenue | 4.31 Bil | 4.33 Bil | 4.35 Bil | 0.2% | Raised | Guidance: 4.32 Bil for 2026 | |
| 2026 CVI Revenue | 2.91 Bil | 2.92 Bil | 2.93 Bil | 0.2% | Raised | Guidance: 2.91 Bil for 2026 | |
| 2026 CSI Revenue | 1.40 Bil | 1.41 Bil | 1.41 Bil | 0.0% | Raised | Guidance: 1.41 Bil for 2026 | |
| 2026 Non-GAAP Diluted EPS | 4.58 | 4.62 | 4.66 | 2.1% | Raised | Guidance: 4.53 for 2026 | |
| 2026 Free Cash Flow | 600.00 Mil | 612.50 Mil | 625.00 Mil | 2.1% | Raised | Guidance: 600.00 Mil for 2026 | |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lucchese, Cynthia L | Direct | Buy | 12232025 | 84.06 | 1,784 | 149,963 | 793,947 | Form | |
| 2 | Rivas, Maria | see footnote | Buy | 12192025 | 82.13 | 1,000 | 82,130 | 915,010 | Form | |
| 3 | Kurzius, Lawrence Erik | Direct | Buy | 12172025 | 82.50 | 2,000 | 165,000 | 641,602 | Form | |
| 4 | Sheffield, Holly R | President, CSI | Direct | Buy | 12162025 | 80.75 | 1,230 | 99,322 | 3,153,449 | Form |
| 5 | White, Albert G Iii | President & CEO | Direct | Buy | 12162025 | 80.80 | 10,000 | 808,000 | 19,081,001 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lucchese, Cynthia L | Direct | Buy | 12232025 | 84.06 | 1,784 | 149,963 | 793,947 | Form | |
| 2 | Rivas, Maria | see footnote | Buy | 12192025 | 82.13 | 1,000 | 82,130 | 915,010 | Form | |
| 3 | Kurzius, Lawrence Erik | Direct | Buy | 12172025 | 82.50 | 2,000 | 165,000 | 641,602 | Form | |
| 4 | Sheffield, Holly R | President, CSI | Direct | Buy | 12162025 | 80.75 | 1,230 | 99,322 | 3,153,449 | Form |
| 5 | White, Albert G Iii | President & CEO | Direct | Buy | 12162025 | 80.80 | 10,000 | 808,000 | 19,081,001 | Form |
| 6 | Kurzius, Lawrence Erik | Direct | Buy | 9292025 | 68.39 | 2,000 | 136,780 | 395,089 | Form | |
| 7 | White, Albert G Iii | President & CEO | Direct | Buy | 9052025 | 68.39 | 10,000 | 683,900 | 15,466,467 | Form |
| 8 | Warner, Gerard H Iii | President, CooperVision, Inc. | Direct | Buy | 9052025 | 69.23 | 1,450 | 100,384 | 1,268,224 | Form |
| 9 | McBride, Daniel G | EVP & Chief Operating Officer | Direct | Buy | 9022025 | 65.04 | 3,000 | 195,120 | 4,105,325 | Form |
| 10 | Andrews, Brian G | EVP, CFO & Treasurer | See footnote | Buy | 9022025 | 65.68 | 1,525 | 100,162 | 1,457,505 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/1/2026